GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-Asset

NKGen Biotech (NKGen Biotech) Debt-to-Asset : 1.36 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Debt-to-Asset?

NKGen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $11.72 Mil. NKGen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $10.50 Mil. NKGen Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $16.32 Mil. NKGen Biotech's debt to asset for the quarter that ended in Mar. 2024 was 1.36.

NKGen Biotech Debt-to-Asset Historical Data

The historical data trend for NKGen Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Debt-to-Asset Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Asset
2.88 0.74 1.21

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial 0.74 - 0.80 1.21 1.36

Competitive Comparison of NKGen Biotech's Debt-to-Asset

For the Biotechnology subindustry, NKGen Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Debt-to-Asset falls into.


NKGen Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NKGen Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(9.991 + 9.93) / 16.481
=1.21

NKGen Biotech's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(11.719 + 10.495) / 16.316
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech  (NAS:NKGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NKGen Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-Asset
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.